Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These medications include sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), both of which also have established efficacy in lowering glucose in youth (<18 years) with T2DM [61-63].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
Arslanian, S., Bacha, F., Grey, M., Marcus, M. D., White, N. H., & Zeitler, P. (2018) · Diabetes Care · doi:10.2337/dci18-0052 · Cited by 349
Self-citation
Research works printed but not linked: 22
- Darnton-Hill, 2004, A life course approach to diet, nutrition and the prevention of chronic diseases, Public Health Nutr, 7, 101, 10.1079/PHN2003584 · DOI · Paper page
- Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes, Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
- Lawrence, 2021, Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001–2017, JAMA, 326, 717, 10.1001/jama.2021.11165 · DOI · Paper page
- 2013, Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial, Diabetes Care, 36, 1735, 10.2337/dc12-2420 · DOI · Paper page
- Dabelea, 2017, Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood, JAMA, 317, 825, 10.1001/jama.2017.0686 · DOI · Paper page
- Shah, 2022, ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents, Pediatr Diabetes, 23, 872, 10.1111/pedi.13409 · DOI · Paper page
- Arslanian, 2022, Once-weekly dulaglutide for the treatment of youths with type 2 diabetes, N Engl J Med, 387, 433, 10.1056/NEJMoa2204601 · DOI · Paper page
- Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N Engl J Med, 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
- Tamborlane, 2022, Once-weekly exenatide in youth with type 2 diabetes, Diabetes Care, 45, 1833, 10.2337/dc21-2275 · DOI · Paper page
- Shankar, 2022, A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes, Pediatr Diabetes, 23, 173, 10.1111/pedi.13279 · DOI · Paper page
- Tamborlane, 2022, Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study, Lancet Diabetes Endocrinol, 10, 341, 10.1016/S2213-8587(22)00052-3 · DOI
- Laffel, 2018, Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial, Diabet Med, 35, 1096, 10.1111/dme.13629 · DOI
- Tamborlane, 2018, Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes, Pediatr Diabetes, 19, 640, 10.1111/pedi.12616 · DOI
- Karres, 2014, Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes, Diabetes Care, 37, 2665, 10.2337/dc14-0494 · DOI
- Mangione, 2022, Screening for prediabetes and type 2 diabetes in children and adolescents: US Preventive Services Task Force recommendation statement, JAMA, 328, 963, 10.1001/jama.2022.14543 · DOI · Paper page
- Isganaitis, 2022, Recommendations for screening children and adolescents for prediabetes and type 2 diabetes, JAMA, 328, 933, 10.1001/jama.2022.13759 · DOI
- Jonas, 2022, Screening for prediabetes and type 2 diabetes in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force, JAMA, 328, 968, 10.1001/jama.2022.7957 · DOI
- Tamborlane, 2018, Eligibility for clinical trials is limited for youth with type 2 diabetes: insights from the pediatric diabetes consortium T2D clinic registry, Pediatr Diabetes, 19, 1379, 10.1111/pedi.12763 · DOI
- Mansournia, 2016, Inverse probability weighting, BMJ, 352, i189, 10.1136/bmj.i189 · DOI · Paper page
- Zeitler, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes, N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
- Bacha, 2018, Initial presentation of type 2 diabetes in adolescents predicts durability of successful treatment with metformin monotherapy: insights from the pediatric diabetes consortium T2D registry, Horm Res Paediatr, 89, 47, 10.1159/000481687 · DOI
- Malik, 2022, Trends in glycemic control among youth and young adults with diabetes: the SEARCH for diabetes in youth study, Diabetes Care, 45, 285, 10.2337/dc21-0507 · DOI · Paper page
Cited by
14. Children and Adolescents: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s014 · Cited by 173
Self-citationManaging early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Metadata
- Authors
- Laffel, L. M., Danne, T., Klingensmith, G. J., Tamborlane, W. V., Willi, S., Zeitler, P., Neubacher, D., Marquard, J., Bardymova, T., Barrientos Perez, M., Bethin, K., Bjornstad, P., Bondar, I., Chen, M., Choi, J.-H., Clements, M. A., Colomar, J. R., Daniels, M., Deerochanawong, C., Desai, V. S., Desmangles, J.-C. G., Dillon, R. G., Dixit, N. M., Du, H., Edelen, R., Espinoza Peralta, D., Felipe Gacioppo, M. V., Ferraz, T. M. B. L., Galkina, G., Gallagher, M. P., George, M., Gonzalez, E., Gottschalk, M. E., Guido, G., Hassan, A. A., Hershkovitz, E., Huerta-Saenz, L. P., Hwang, J. S., Ibarra Gomez, J. O., Irizarry Gonzalez, L., Jain, N., Jelley, D. H., Kim, H.-S., Kovalenko, T., Laffel, L. M. B., Leichter, S. B., Liberatore Jr, R. D. R., Lynch, J., Mahmud, F. H., Malievskiy, O. A., Muir, A., Nelson, B. A., Nevarez Ruiz, L. A., Olson, M. L., Pelayo Orozco, E. S., Peterkova, V., Ramírez Mendoza, F. R., Reddy, K. M., Rodriguez, H., Saenz, J. A., Samoilova, J., Schwab, K.-O., Shah, S. H., Shehadeh, N., Shoemaker, A. H., Skorodok, Y., Sobolev, A., Solís, S. E., Srinivasan, S., Tamborlane, W. V., Tsalikian, E., Valeeva, F., Vance, C. D., Velasquez-Mieyer, P. A., Violante Ortiz, R. M., Votyakova, O., Wei, H., Weinstock, R. S., Wheeler, M. D., Wicklow, B. A., Willi, S. M., Wintergerst, K. A., Wolf, R. M., Wood, J. R., Yaliwal, C., & Yupanqui Lozno, H.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 11
- Issue
- 3
- Pages
- 169-181
- ISSN
- 2213-8587
- Cited by
- 106
- References
- 14
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Boehringer Ingelheim
- Boehringer Ingelheim International GmbH
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00387-4
- The paper
- Laffel, L. M., Danne, T., Klingensmith, G. J., Tamborlane, W. V., Willi, S., Zeitler, P., Neubacher, D., Marquard, J., Bardymova, T., Barrientos Perez, M., Bethin, K., Bjornstad, P., Bondar, I., Chen, M., Choi, J.-H., Clements, M. A., Colomar, J. R., Daniels, M., Deerochanawong, C., . . . Yupanqui Lozno, H. (2023). Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00387-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.